Radioactive therapy shows promise for kids with neuroblastoma

NCT ID NCT03966651

Completed Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a radioactive drug called 177Lu-DOTATATE in one child with neuroblastoma that had come back or not responded to standard treatments. The drug targets tumor cells that have a specific marker (somatostatin receptors). The goal was to find a safe dose. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-DOTATATE (a radioactive drug that targets tumor cells)
What this could lead to: If it works, this could point toward a new treatment option for children with hard-to-treat neuroblastoma.
What could go wrong: This is a very early phase 1 trial with only 1 participant, so safety and effectiveness are not yet known. The treatment involves radiation, which carries risks like damage to healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

CHU Angers

Angers, France
CHU Besançon

Besançon, France
CHU Dijon

Dijon, France
CHU Nancy

Nancy, France
CHU Nantes

Nantes, France
CHU Pellegrin

Bordeaux, France
CHU Reims

Reims, France
CHU Strasbourg

Strasbourg, France
CHU de Grenoble

Grenoble, France
CHU de Toulouse - Hôpital des enfants

Toulouse, France
Centre Léon Bérard

Lyon, France
Centre Oscar Lambret

Lille, France
Hopital Arnaud de Villeneuve

Montpellier, France
IUCT-O

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.